NCT03054402View on ClinicalTrials.gov

First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 13, 2017

Primary Completion Date

November 30, 2017

Study Completion Date

March 29, 2018

Conditions
Pelvic Inflammatory Disease
Interventions
DRUG

BAY1834845

Escalating doses of BAY1834845 including comparison of solution and tablet in one dose group

DRUG

Placebo

Single dose of placebo

Trial Locations (1)

13353

CRS Clinical Research Services Berlin GmbH, Berlin

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY